Page 204 - 2019_12-Haematologica-web

B. de la Morena-Barrio et al.
II (99 Leu to Phe mutation) and childhood
thromboembolism. Thromb Haemost.
2001;86(4):1007-1011.
15. Sarper N, Orlando C, Demirsoy U, Gelen
SA, Jochmans K. Homozygous antithrom- bin deficiency in adolescents presenting with lower extremity thrombosis and renal complications: two case reports from Turkey. J Pediatr Hematol Oncol. 2014;36(3):e190-e192.
16. Limperger V, Franke A, Kenet G, et al. Clinical and laboratory characteristics of paediatric and adolescent index cases with venous thromboembolism and antithrom- bin deficiency. An observational multicentre cohort study. Thromb Haemost. 2014; 112(3):478-485.
17. World Health Organisation. Paediatric Age Categories to be Used in Differentiating Between Listing on a Model Essential Medicines List for Children. Position Pap. 2017. http://archives. who.int/eml/expcom/ children/Items/PositionPaperAgeGroups. pdf
18. Ashby D. Practical statistics for medical research. Douglas G. Altman, Chapman and Hall, London, 1991. No. of pages: 611. Vol. 10. Wiley-Blackwell; 1991. 1635-1636.
19. de la Morena-Barrio ME, Martínez-Martínez I, de Cos C, et al. Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect. J Thromb Haemost. 2016;14(8):1549-1560.
20. Schmidt B, Andrew M. Neonatal thrombo- sis: report of a prospective Canadian and international registry. Pediatrics. 1995;96(5 Pt 1):939-943.
21. Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed. 1997;76(3):F163-167.
22. van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr. 2001;139(5):676-681.
23. Yang JYK, Chan AKC. Pediatric Thrombophilia. Pediatr Clin North Am. 2013;60(6):1443-1462.
24. Toulon P, Berruyer M, Brionne-François M, et al. Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges. Thromb Haemost. 2016;116(1):9-16.
25. Andrew M, Paes B, Milner R, et al.
Development of the human coagulation sys- tem in the full-term infant. Blood. 1987; 70(1):165-172.
26. Greenway A, Massicotte M., Monagle P. Neonatal thrombosis and its treatment. Blood Rev. 2004;18(2):75-84.
27. Brenner B, Fishman A, Goldsher D, Schreibman D, Tavory S. Cerebral thrombo- sis in a newborn with a congenital deficien- cy of antithrombin III. Am J Hematol. 1988; 27(3):209-211.
28. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Am J Med. 1989; 87(3):S3-S38.
29. Kenet G, Lutkhoff LK, Albisetti M, et al. Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children: A Systematic Review and Meta-Analysis of Observational Studies. Circulation. 2010; 121(16):1838-1847.
30. Berfelo FJ, Kersbergen KJ, van Ommen CH, et al. Neonatal Cerebral Sinovenous Thrombosis From Symptom to Outcome. Stroke. 2010;41(7):1382-1388.
31. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic dis- ease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000; 47(6):763-766.
32. Rosendaal FR, Heijboer H. Mortality related to thrombosis in congenital antithrombin III deficiency. Lancet. 1991;337(8756):1545.
33. van Boven H, Olds R, Thein S, et al. Hereditary antithrombin deficiency: hetero- geneity of the molecular basis and mortality in Dutch families. Blood. 1994;84(12)4209- 4213.
34. Gindele R, Oláh Z, Ilonczai P, et al. Founder effect is responsible for the p.Leu131Phe heparin-binding-site antithrombin mutation common in Hungary: phenotype analysis in a large cohort. J Thromb Haemost. 2016;14(4):704-715.
35. Corral J, Huntington JA, González-Conejero R, et al. Mutations in the shutter region of antithrombin result in formation of disul- fide-linked dimers and severe venous thrombosis. J Thromb Haemost. 2004; 2(6):931-939.
36. Corral J, Vicente V, Carrell RW. Thrombosis as a conformational disease. Haematologica. 2005;90(2):238-246.
37. Raffini L. Thrombophilia in Children: Who to Test, How, When, and Why? Hematology. 2008;2008(1):228-235.
38. van Ommen CH, Middeldorp S. Thrombophilia in Childhood: To Test or Not to Test. Semin Thromb Hemost. 2011;37(07):794-801.
39. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S-e801S.
40. Gavva C, Sarode R, Zia A. A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: impact on management. Blood Adv. 2017; 1(25): 2386-2391.
41. Nowak-Göttl U, van Ommen H, Kenet G. Thrombophilia testing in children: What and when should be tested? Thromb Res. 2018;164:75-78.
42. Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood. 2002;100(7):2403-2405.
43. Mahmoodi BK, Brouwer J-LP, Ten Kate MK, et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asympto- matic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost. 2010; 8(6):1193-1200.
44. Rühle F, Stoll M. Advances in predicting venous thromboembolism risk in children. Br J Haematol. 2018;180(5):654-665.
45. De Stefano V, Leone G, Mastrangelo S, et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 1994;72(3):352-358.
46. De Stefano V, Leone G, Mastrangelo S, et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 1994;71(6):799-800.
47. Kovács B, Bereczky Z, Oláh Z, et al. The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site antithrombin deficiency. Am J Clin Pathol. 2013;140(5):675-679.
48. Corral J, Vicente V. Puzzling questions on antithrombin: Diagnostic limitations and real incidence in venous and arterial throm- bosis. Thromb Res. 2015;135(6):1047-1048.
2518
haematologica | 2019; 104(12)